{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:45:25Z","timestamp":1773873925072,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2019C03050"],"award-info":[{"award-number":["2019C03050"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003248"],"award-info":[{"award-number":["82003248"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iLIVER"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.iliver.2022.03.003","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T12:15:40Z","timestamp":1648469740000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment?"],"prefix":"10.1016","volume":"1","author":[{"given":"Xun","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengqiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4152-8752","authenticated-orcid":false,"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhensheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuxiao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-2811","authenticated-orcid":false,"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.iliver.2022.03.003_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N.\u00a0\u200bEngl. J. Med."},{"key":"10.1016\/j.iliver.2022.03.003_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jconrel.2017.11.031","article-title":"A\u00a0\u200bnovel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways","volume":"269","author":"Yang","year":"2018","journal-title":"J.\u00a0\u200bContr. Release"},{"key":"10.1016\/j.iliver.2022.03.003_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.iliver.2022.03.003_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J.\u00a0\u200bHepatol."},{"key":"10.1016\/j.iliver.2022.03.003_bib5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.iliver.2022.03.003_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.iliver.2022.03.003_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/med.21514","article-title":"Complex roles of the old drug aspirin in cancer chemoprevention and therapy","volume":"39","author":"Hua","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.iliver.2022.03.003_bib8","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of aspirin with hepatocellular carcinoma and liver-related mortality","volume":"382","author":"Simon","year":"2020","journal-title":"N.\u00a0\u200bEngl. J. Med"},{"key":"10.1016\/j.iliver.2022.03.003_bib9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamaoncol.2015.6396","article-title":"Population-wide impact of long-term use of aspirin and the risk for cancer","volume":"2","author":"Cao","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.iliver.2022.03.003_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019008","article-title":"Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis","volume":"99","author":"Shin","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.iliver.2022.03.003_bib11","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.iliver.2022.03.003_bib12","first-page":"2109","article-title":"Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis","volume":"6","author":"Li","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.iliver.2022.03.003_bib13","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.iliver.2022.03.003_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41401-018-0014-x","article-title":"Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism","volume":"40","author":"Liu","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.iliver.2022.03.003_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3892\/or.2020.7630","article-title":"Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis","volume":"44","author":"Shi","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.iliver.2022.03.003_bib16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/jhep.2002.32676","article-title":"Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells","volume":"35","author":"Abiru","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.iliver.2022.03.003_bib17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bbrc.2017.03.139","article-title":"Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFkappaB-ACSL1 signaling","volume":"486","author":"Yang","year":"2017","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.iliver.2022.03.003_bib18","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.3892\/mmr.2016.4980","article-title":"Protectin D1 reduces concanavalin A-induced liver injury by inhibiting NF-kappaB-mediated CX3CL1\/CX3CR1 axis and NLR family, pyrin domain containing 3 inflammasome activation","volume":"13","author":"Ren","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.iliver.2022.03.003_bib19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.14520","article-title":"The aspirin story - from willow to wonder drug","volume":"177","author":"Desborough","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.iliver.2022.03.003_bib20","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1111\/bcp.13355","article-title":"Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people","volume":"83","author":"Ardoino","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.iliver.2022.03.003_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J.\u00a0\u200bHepatol."},{"key":"10.1016\/j.iliver.2022.03.003_bib22","doi-asserted-by":"crossref","first-page":"686962","DOI":"10.3389\/fonc.2021.686962","article-title":"Risk factors and prevention of viral hepatitis-related hepatocellular carcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.iliver.2022.03.003_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/jvh.12446","article-title":"Aspirin inhibits hepatitis C virus entry by downregulating claudin-1","volume":"23","author":"Yin","year":"2016","journal-title":"J.\u00a0\u200bViral Hepat."},{"key":"10.1016\/j.iliver.2022.03.003_bib24","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/hep.22215","article-title":"Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways","volume":"47","author":"Trujillo-Murillo","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.iliver.2022.03.003_bib25","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1007\/s00705-014-2201-5","article-title":"Downregulation of inducible nitric oxide synthase (iNOS) expression is implicated in the antiviral activity of acetylsalicylic acid in HCV-expressing cells","volume":"159","author":"Rios-Ibarra","year":"2014","journal-title":"Arch. Virol."},{"key":"10.1016\/j.iliver.2022.03.003_bib26","doi-asserted-by":"crossref","first-page":"G1264","DOI":"10.1152\/ajpgi.00237.2011","article-title":"Cu\/Zn superoxide dismutase (SOD1) induction is implicated in the antioxidative and antiviral activity of acetylsalicylic acid in HCV-expressing cells","volume":"302","author":"Rivas-Estilla","year":"2012","journal-title":"Am. J. Physiol. Gastrointest Liver Physiol."},{"key":"10.1016\/j.iliver.2022.03.003_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2018.8342","article-title":"Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"179","author":"Lee","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.iliver.2022.03.003_bib28","article-title":"Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis","author":"Jang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.iliver.2022.03.003_bib29","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1016\/j.cgh.2020.04.036","article-title":"Association of daily aspirin therapy with hepatocellular carcinoma risk in patients with chronic hepatitis C virus infection","volume":"18","author":"Lee","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.iliver.2022.03.003_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12876-020-1158-y","article-title":"Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study","volume":"20","author":"Liao","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.iliver.2022.03.003_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-021-03247-1","article-title":"Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease","author":"Yi","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.iliver.2022.03.003_bib32","doi-asserted-by":"crossref","first-page":"569759","DOI":"10.3389\/fmed.2020.569759","article-title":"Aspirin use and the incidence of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis of cohort studies","volume":"7","author":"Li","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.iliver.2022.03.003_bib33","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ejca.2012.02.009","article-title":"Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis","volume":"48","author":"Liu","year":"2012","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.iliver.2022.03.003_bib34","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.iliver.2022.03.003_bib35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","article-title":"Hepatocellular carcinoma in the setting of alcohol-related liver disease","volume":"70","author":"Ganne-Carrie","year":"2019","journal-title":"J.\u00a0\u200bHepatol."},{"key":"10.1016\/j.iliver.2022.03.003_bib36","doi-asserted-by":"crossref","first-page":"7806860","DOI":"10.1155\/2020\/7806860","article-title":"Aspirin improves nonalcoholic fatty liver disease and atherosclerosis through regulation of the PPARdelta-AMPK-PGC-1alpha pathway in dyslipidemic conditions","volume":"2020","author":"Han","year":"2020","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.iliver.2022.03.003_bib37","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41374-018-0144-2","article-title":"Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero","volume":"99","author":"Zhou","year":"2019","journal-title":"Lab. Invest."},{"key":"10.1016\/j.iliver.2022.03.003_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.iliver.2022.03.003_bib39","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.18632\/aging.103002","article-title":"Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4\/NF-kappaB pathway","volume":"12","author":"Liu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.iliver.2022.03.003_bib40","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.3748\/wjg.v23.i35.6412","article-title":"Effects of aspirin and enoxaparin in a rat model of liver fibrosis","volume":"23","author":"Li","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.iliver.2022.03.003_bib41","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13515","article-title":"Aspirin use is associated with lower indices of liver fibrosis among adults in the United States","volume":"43","author":"Jiang","year":"2016","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.iliver.2022.03.003_bib42","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/jnci\/djs452","article-title":"Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma","volume":"104","author":"Sahasrabuddhe","year":"2012","journal-title":"J.\u00a0\u200bNatl. Cancer Inst."},{"key":"10.1016\/j.iliver.2022.03.003_bib43","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1940-6207.CAPR-15-0126","article-title":"NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project","volume":"8","author":"Petrick","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.iliver.2022.03.003_bib44","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/hep.29318","article-title":"Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment","volume":"66","author":"Lee","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.iliver.2022.03.003_bib45","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2018.4154","article-title":"Association between aspirin use and risk of hepatocellular carcinoma","volume":"4","author":"Simon","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.iliver.2022.03.003_bib46","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1038\/s41598-018-23343-0","article-title":"Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults","volume":"8","author":"Hwang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.iliver.2022.03.003_bib47","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.3748\/wjg.v25.i28.3798","article-title":"Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: a retrospective single-center study","volume":"25","author":"Du","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.iliver.2022.03.003_bib48","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1111\/liv.15011","article-title":"Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: a nationwide population-based study","volume":"41","author":"Choi","year":"2021","journal-title":"Liver. Int."},{"key":"10.1016\/j.iliver.2022.03.003_bib49","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000324","article-title":"Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B receiving oral nucleos(t)ide analog","volume":"12","author":"Hui","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.iliver.2022.03.003_bib50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MCG.0000000000001546","article-title":"Combined use of aspirin and statin is associated with a decreased incidence of hepatocellular carcinoma","volume":"56","author":"Singh","year":"2022","journal-title":"J.\u00a0\u200bClin. Gastroenterol."},{"key":"10.1016\/j.iliver.2022.03.003_bib51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jfma.2019.04.018","article-title":"Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection","volume":"119","author":"Young","year":"2020","journal-title":"J.\u00a0\u200bFormos. Med. Assoc."},{"key":"10.1016\/j.iliver.2022.03.003_bib52","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1245\/s10434-016-5520-9","article-title":"Antiplatelet therapy is associated with a better prognosis for patients with hepatitis B virus-related hepatocellular carcinoma after liver resection","volume":"23","author":"Lee","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.iliver.2022.03.003_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2214\/AJR.18.20846","article-title":"Aspirin is associated with improved liver function after embolization of hepatocellular carcinoma","volume":"213","author":"Boas","year":"2019","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.iliver.2022.03.003_bib54","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.hpb.2020.09.024","article-title":"Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib","volume":"23","author":"Casadei-Gardini","year":"2021","journal-title":"HPB"},{"key":"10.1016\/j.iliver.2022.03.003_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113215","article-title":"Antiplatelet therapy improves the prognosis of patients with hepatocellular carcinoma","volume":"12","author":"Hayashi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.iliver.2022.03.003_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246376","article-title":"Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: a tale of multiple confounders","volume":"13","author":"Ielasi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.iliver.2022.03.003_bib57","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2019.06.048","article-title":"Aspirin targets P4HA2 through inhibiting NF-kappaB and LMCD1-AS1\/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma","volume":"45","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.iliver.2022.03.003_bib58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2017.06.029","article-title":"Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition","volume":"406","author":"Sun","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.iliver.2022.03.003_bib59","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.1038\/sj.onc.1208169","article-title":"Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation","volume":"23","author":"Takada","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.iliver.2022.03.003_bib60","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejphar.2015.08.049","article-title":"COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance","volume":"785","author":"Poorani","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.iliver.2022.03.003_bib61","first-page":"35","article-title":"Reduction of high-fat diet-induced liver proinflammatory state by eicosapentaenoic acid plus hydroxytyrosol supplementation: involvement of resolvins RvE1\/2 and RvD1\/2","volume":"63","author":"Echeverria","year":"2019","journal-title":"J.\u00a0\u200bNutr. Biochem."},{"key":"10.1016\/j.iliver.2022.03.003_bib62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1753425916628618","article-title":"Resolvin D1, resolvin D2 and maresin 1 activate the GSK3beta anti-inflammatory axis in TLR4-engaged human monocytes","volume":"22","author":"Gu","year":"2016","journal-title":"Innate. Immun."},{"key":"10.1016\/j.iliver.2022.03.003_bib63","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1167\/iovs.09-4468","article-title":"Dependence of resolvin-induced increases in corneal epithelial cell migration on EGF receptor transactivation","volume":"51","author":"Zhang","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.iliver.2022.03.003_bib64","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1158\/1535-7163.MCT-09-0551","article-title":"Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2","volume":"8","author":"Lim","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.iliver.2022.03.003_bib65","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1158\/0008-5472.CAN-07-2295","article-title":"Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids","volume":"68","author":"Lim","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.iliver.2022.03.003_bib66","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neo.2017.12.004","article-title":"COX-2 forms regulatory loop with YAP to promote proliferation and tumorigenesis of hepatocellular carcinoma cells","volume":"20","author":"Xu","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.iliver.2022.03.003_bib67","first-page":"981","article-title":"Effects of aspirin on hepatocellular carcinoma and its potential molecular mechanism","volume":"25","author":"Yuan","year":"2020","journal-title":"J.\u00a0\u200bBUON."},{"key":"10.1016\/j.iliver.2022.03.003_bib68","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3892\/or.2014.3074","article-title":"Prostaglandin E(2) receptor EP2 mediates Snail expression in hepatocellular carcinoma cells","volume":"31","author":"Cheng","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.iliver.2022.03.003_bib69","article-title":"Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma","volume":"8","author":"Lu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.iliver.2022.03.003_bib70","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/abbs\/gmv112","article-title":"Down-regulation of SDF1-alpha expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma","volume":"47","author":"Lu","year":"2015","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.iliver.2022.03.003_bib71","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.2147\/CMAR.S183376","article-title":"Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2","volume":"11","author":"Tai","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.iliver.2022.03.003_bib72","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.12659\/MSM.919218","article-title":"Celecoxib inhibits hepatocellular carcinoma cell growth and migration by targeting PNO1","volume":"25","author":"Dai","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.iliver.2022.03.003_bib73","doi-asserted-by":"crossref","first-page":"7806860","DOI":"10.1155\/2020\/7806860","article-title":"Aspirin improves nonalcoholic fatty liver disease and atherosclerosis through regulation of the PPARdelta-AMPK-PGC-1alpha pathway in dyslipidemic conditions","volume":"2020","author":"Han","year":"2020","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.iliver.2022.03.003_bib74","series-title":"Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway","author":"He","year":"2015"},{"key":"10.1016\/j.iliver.2022.03.003_bib75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev.immunol.25.022106.141647","article-title":"Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways","volume":"25","author":"Serhan","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.iliver.2022.03.003_bib76","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ijo.2017.226","article-title":"Maresin 1 mitigates liver steatosis in ob\/ob and diet-induced obese mice","volume":"42","author":"Laiglesia","year":"2018","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.iliver.2022.03.003_bib77","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1074\/jbc.RA117.000885","article-title":"Maresin 1 attenuates NAFLD by suppression of endoplasmic reticulum stress via AMPK-SERCA2b pathway","volume":"293","author":"Jung","year":"2018","journal-title":"J.\u00a0\u200bBiol. Chem."},{"key":"10.1016\/j.iliver.2022.03.003_bib78","doi-asserted-by":"crossref","first-page":"14609","DOI":"10.1021\/bi00044a041","article-title":"Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils","volume":"34","author":"Serhan","year":"1995","journal-title":"Biochem.-US"},{"key":"10.1016\/j.iliver.2022.03.003_bib79","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2015.03.083","article-title":"Lipoxins and aspirin-triggered lipoxins in resolution of inflammation","volume":"760","author":"Romano","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.iliver.2022.03.003_bib80","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1172\/JCI1578","article-title":"Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues","volume":"101","author":"Takano","year":"1998","journal-title":"J.\u00a0\u200bClin. Invest."},{"key":"10.1016\/j.iliver.2022.03.003_bib81","doi-asserted-by":"crossref","first-page":"C988","DOI":"10.1152\/ajpcell.1999.276.4.C988","article-title":"LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation","volume":"276","author":"Gewirtz","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.iliver.2022.03.003_bib82","doi-asserted-by":"crossref","first-page":"13266","DOI":"10.1073\/pnas.202296999","article-title":"Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B\u00a0\u200band\u00a0\u200bAP-1 activation, and IL-8 gene expression in human leukocytes","volume":"99","author":"Jozsef","year":"2002","journal-title":"Proc. Natl.\u00a0\u200bAcad. Sci. U S A"},{"key":"10.1016\/j.iliver.2022.03.003_bib83","first-page":"1923","article-title":"Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis","volume":"189","author":"Hachicha","year":"1999","journal-title":"J.\u00a0\u200bExp. Med."},{"key":"10.1016\/j.iliver.2022.03.003_bib84","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1038\/onc.2011.112","article-title":"Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2","volume":"30","author":"Li","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.iliver.2022.03.003_bib85","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1096\/fj.13-235614","article-title":"Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis","volume":"28","author":"Rius","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.iliver.2022.03.003_bib86","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/JLB.3HI0517-206RR","article-title":"Frontline Science: specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome","volume":"105","author":"Lopategi","year":"2019","journal-title":"J.\u00a0\u200bLeukoc. Biol."},{"key":"10.1016\/j.iliver.2022.03.003_bib87","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood-2017-12-820779","article-title":"GPIbalpha is required for platelet-mediated hepatic thrombopoietin generation","volume":"132","author":"Xu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.iliver.2022.03.003_bib88","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/ijc.31022","article-title":"By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma","volume":"141","author":"Li","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.iliver.2022.03.003_bib89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1042\/BJ20150125","article-title":"Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity","volume":"468","author":"Ford","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.iliver.2022.03.003_bib90","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.redox.2015.08.014","article-title":"Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling","volume":"6","author":"Vannini","year":"2015","journal-title":"Redox Biol."},{"key":"10.1016\/j.iliver.2022.03.003_bib91","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.bcp.2011.12.018","article-title":"Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect","volume":"83","author":"Chattopadhyay","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.iliver.2022.03.003_bib92","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/carcin\/bgy049","article-title":"Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway","volume":"39","author":"Song","year":"2018","journal-title":"Carcinogenesis"}],"container-title":["iLIVER"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947822000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947822000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:37:29Z","timestamp":1757425049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772947822000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2772947822000093"],"URL":"https:\/\/doi.org\/10.1016\/j.iliver.2022.03.003","relation":{},"ISSN":["2772-9478"],"issn-type":[{"value":"2772-9478","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment?","name":"articletitle","label":"Article Title"},{"value":"iLIVER","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iliver.2022.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}]}}